VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2022 | Long-term efficacy of adjunctive cenobamate in patients with focal seizures

Cenobamate is a relatively new antiseizure medication approved in Europe in March 2021 for the adjunctive treatment of focal seizures in adult epilepsy patients whose seizures have not been adequately controlled despite a history of treatment with at least two anti-epileptic drugs. Christian Brandt, MD, Bielefeld University, Medical School, Bielefeld, Germany, talks on the long-term efficacy of adjunctive cenobamate in patients with uncontrolled focal seizures. Data from open-label extension studies of the pivotal trials have shown that cenobamate is effective and generally well tolerated. Those results reflect what is observed in clinical practice. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.

Disclosures

Honoraria for speaking or consulting activities from Angelini/Arvelle, Eisai, Equilibre, GW Pharmaceuticals, Johnson&Johnson, Marinus, UCB Pharma, Xenon and Zogenix